Dechra Pharmaceuticals PLC
LSE:DPH

Watchlist Manager
Dechra Pharmaceuticals PLC Logo
Dechra Pharmaceuticals PLC
LSE:DPH
Watchlist
Price: 3 866 GBX Market Closed
Updated: May 20, 2024

P/E
Price to Earnings

-15 783.5
Current
6 502.3
Median
23.5
Industry
Lower than median
Lower than industry value

Price to Earnings (P/E) ratio is a valuation multiple that compares a company’s market capitalization to its net income. It indicates the dollar amount an investor can expect to invest in a company in order to receive $1 of that company’s earnings.

P/E
-15 783.5
=
Market Cap
440.4B
/
Net Income
-27.9m
All Countries
Close
Market Cap P/E
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP -15 783.5
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY -5 347 888.9
US
Eli Lilly and Co
NYSE:LLY
742.2B USD 121.2
DK
Novo Nordisk A/S
CSE:NOVO B
4T DKK 45.1
US
Johnson & Johnson
NYSE:JNJ
366.6B USD 9.5
US
Merck & Co Inc
NYSE:MRK
333.1B USD 144.4
UK
AstraZeneca PLC
LSE:AZN
187.5B GBP 37.6
CH
Roche Holding AG
SIX:ROG
189B CHF 16.4
CH
Novartis AG
SIX:NOVN
182.7B CHF 11.5
US
Pfizer Inc
NYSE:PFE
162.6B USD -526.1
FR
Sanofi SA
PAR:SAN
111.8B EUR 12.3
Earnings Growth
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Average P/E: 49.8
Negative Multiple: -15 783.5
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
121.2
346%
DK
Novo Nordisk A/S
CSE:NOVO B
45.1
84%
US
Johnson & Johnson
NYSE:JNJ
9.5
-21%
US
Merck & Co Inc
NYSE:MRK
144.4
7 453%
UK
AstraZeneca PLC
LSE:AZN
37.6
168%
CH
Roche Holding AG
SIX:ROG
16.4
26%
CH
Novartis AG
SIX:NOVN
11.5
15%
US
Pfizer Inc
NYSE:PFE
Negative Multiple: -526.1
680%
FR
Sanofi SA
PAR:SAN
12.3
120%

P/E Forward Multiples

Forward P/E multiple is a version of the P/E ratio that uses forecasted net income for the P/E calculation. 1-Year, 2-Years, and 3-Years forwards use net income forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
P/E
hidden
2-Years Forward
P/E
hidden
3-Years Forward
P/E
hidden

See Also

Discover More